Sign Up
Stories
Takeda's HYQVIA Approved as CIDP Maintenance Therapy
Share
Advancements in Immunotherapy for Neurol...
Takeda's HYQVIA® Positively Receives CHM...
Overview
API
Takeda's HYQVIA is approved by the European Commission as a maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). The therapy offers the potential for monthly in-office or at-home infusions, providing a significant reduction in CIDP relapse rates.
Ask a question
How does HYQVIA's approval impact the treatment landscape for CIDP patients in Europe?
How might Takeda's advancement in CIDP treatment influence the development of similar therapies for other neurological conditions?
What are the potential implications of HYQVIA's approval for patients with other immunodeficiencies?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage